Friday , 21 February 2025
0

No products in the cart.

Worldwide News Worldwide News
0

No products in the cart.

Home Health AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition
Health

AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition

March 25, 20241 Mins read112 Views
AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition

AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis. Preliminary proof-of-concept data from a Phase 2 study are expected later this year.

ICYMI: Fed's Bostic spoke again on Monday, repeated his forecast for just 1 cut this year Previous post ICYMI: Fed's Bostic spoke again on Monday, repeated his forecast for just 1 cut this year

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Health

This year’s ViVE conference was full of announcements — from acquisitions to...

ByFebruary 21, 2025
Health

Do you think hormones cause mood swings in women only?It is not...

ByFebruary 20, 2025

PEPFAR, the U.S. global HIV/AIDS program, is - for the first time...

ByFebruary 20, 2025

In Feedspot’s 2025 rankings, Healthcare Economist was once again ranked in the...

ByFebruary 20, 2025

Abous us

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis

Subscribe Now

    Subscribe to our mailing list to receives daily updates direct to your inbox!
    © Copyright 2022 Jellywp. All rights reserved powered by Jellywp.com